Vikia hiv 1 2

Manufactured by bioMérieux

Sourced in France, Japan

The Vikia HIV-1/2 is a rapid diagnostic test designed for the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma, or whole blood samples. It provides a simple, fast, and reliable method for the preliminary identification of individuals infected with HIV.

Automatically generated - may contain errors

Lab products found in correlation

Determine hiv 1 2, by Abbott (2 mentions) Uni gold hiv 1 2, by Trinity Biotech (2 mentions) Uni gold hiv, by Trinity Biotech (1 mentions) Geenius hiv 1 2 supplemental assay, by Bio-Rad (1 mentions) Facscount, by BD (1 mentions) Bactec9050 system, by BD (1 mentions) Vidas hiv duo ultra, by bioMérieux (1 mentions)

Close spelling variants of this product

Vikia (3 citations)

7 protocols using vikia hiv 1 2

HIV Testing and Outcome Measures in Africa

Check if the same lab product or an alternative is used in the 5 most similar protocols

In Bissau HIV antibody status was obtained with Determine HIV-1/2 (Alere Inc., Massachusetts, USA) and confirmed with First response (Premier Medical Corporation, Daman, India). In Gondar DetermineR HIV-1/2 (Ag/Ab Combo, Orlando, Florida, USA) and Colloidal Gold Device (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.) were used and positive results confirmed with Vikia HIV-1/2 (bioMérieux SA, Lyon, France) and Unigold (Trinity Biotech USA INC, NY, USA).
Pale inferior conjunctivae and palm were considered signs of anemia. The radial artery pulse was counted for 30 s and multiplied by two. A pulse >100 beats/minute was defined as tachycardia. Crepitation, rhonchi and subdued or complete absence of respiratory sounds were defined as positive findings at lung auscultation. A roll-up tape measure was used to assess height. MUAC was measured on the non-dominant arm at the mid-point between acromion and olecranon with a non-stretchable tape (TALC, Herts, UK). Temperature was measured axillary.
Following WHO's (WHO, 2019) definition, failure was defined as death during treatment, loss to follow up and/or treatment failure while treatment completed and cured were defined as non-failure. Patients transferred out were counted as missing outcomes.

Rudolf F., Abate E., Moges B., Mendes A.M., Mengistu M.Y., Sifna A., Fekadu H., Bizuneh S., Schön T, & Wejse C. (2021). Increasing smear positive tuberculosis detection using a clinical score - A stepped wedge multicenter trial from Africa. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 113 Suppl 1.

+ Open protocol

+ Expand

HIV Rapid Testing in Kinshasa

Check if the same lab product or an alternative is used in the 5 most similar protocols

This was an observational study with data collected from February 2017 through July 2018 from 47 clinical sites in 24 health zones in Kinshasa within an approximate 154 square mile (400 km²) area. Participants (primarily adults) received a rapid HIV test at one of 35 hospitals or clinics in 2017 during the pilot phase, and 47 similar sites (12 additional) in 2018. The sites were in different urban health zones and represented a range of available levels of healthcare delivery. Patient’s blood was drawn in an EDTA tube at the collection sites, centrifuged to prepare plasma, and transferred to ice within 2 h to our laboratory at Université Protestante au Congo (UPC). Plasma specimens were tested by HIV serology and confirmed following the National and WHO recommended algorithm at the sites. Multiple rapid tests were used as follows (Determine HIV-1/2 [Determine; Alere, USA], Uni-Gold HIV [Uni-Gold; Trinity Biotech, Ireland], and Vikia HIV 1/2 [Vikia; bioMérieux, France]). All rapid tests have > 99–100% sensitivity and specificity for the detection of HIV-1 and HIV-2.

Pour M., James L., Singh K., Mampunza S., Baer F., Scott J., Berg M.G., Rodgers M.A., Cloherty G.A., Hackett Jr J, & McArthur C.P. (2020). Increased HIV in Greater Kinshasa Urban Health Zones: Democratic Republic of Congo (2017–2018). AIDS Research and Therapy, 17, 67.

+ Open protocol

+ Expand

Substance Use and HIV Cohorts Among PWIDs

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

During both RDS surveys, drug use behaviors were first assessed using both urine testing and a face-to-face questionnaire. Then, the HIV serological status was assessed using the national algorithm, which includes a rapid test (SD BIOLINE HIV1/2 3.0; Standard Diagnostic Inc., Gyeonggi, South Korea). The result was then confirmed by 2 other (rapid) tests (Alere Determine 1/2, Alere Medical Co., Chiba, Japan and VIKIA HIV1/2, bioMerieux, Marcy L’Etoile, France). All HIV-positive PWIDs were offered to participate in a cohort with biannual follow-up visits including a similar questionnaire on drug use behaviors, a HIV viral load assay, and a urine drug test. Likewise, consecutive HIV-negative participants not already on methadone and with available contact details were invited to participate in the HIV-negative cohort (first 441 HIV-negative participants of 2016 survey, first 180 HIV-negative participants of 2017 survey), with similar visit content and HIV testing. In addition, 12 HIV-positive and 66 HIV-negative PWIDs who were participating in a former cohort initiated in 2014 from another RDS survey [17 (link), 18 (link)] were enrolled in the appropriate cohort. Follow-up visits of both cohorts were scheduled within the same time interval. As part of the cohort activities, CBO members facilitated participants’ access to methadone and to ART for those infected with HIV.

Nagot N., Hai V.V., Dong T.T., Hai O.K., Rapoud D., Hoang G.T., Quillet C., Minh K.P., Vallo R., Nham T.T., Castellani J., Feelemyer J., Des Jarlais D.C., Nguyen L.P., Van Le H., Nguyen N.V., Vo L.N., Duong H.T., Moles J.P, & Laureillard D. (2021). Alarming Tuberculosis Rate Among People Who Inject Drugs in Vietnam. Open Forum Infectious Diseases, 9(2), ofab548.

+ Open protocol

+ Expand

Household-Based HIV Testing Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

EPHIA staff used a questionnaire prepared for the survey to collect data about
household and individual characteristics. Initial household-based HIV testing
was performed with the national HIV-testing algorithm using three HIV rapid
tests. Individuals with a reactive screening test underwent confirmatory testing
using the Uni-Gold HIV-1/2 (Trinity Biotech, Bray, Ireland). Individuals with
discordant results were administered a tiebreaker test (Vikia HIV-1/2,
bioMérieux, Marcy-l’Étoile, France). All HIV-positive individuals identified in
the field received confirmatory testing in a satellite laboratory using the
Geenius HIV 1/2 Supplemental Assay (Bio-Rad, Hercules, CA USA) [4 ]. Both the questionnaire
and field laboratory data were collected on mobile tablet devices using the
application Open Data Kit, an open-source mobile data collection application.
The Global Positioning System was used to identify and record the geographical
coordinates of each EPHIA sample location. Cluster geolocation data were loaded
onto encrypted and passcode-protected tablet computers in keyhole markup
language format using the MAPS.ME mobile app (https://maps.me), which includes OpenStreetMap (https://www.openstreetmap.org) data
[25 ].

Gelibo T., Lulseged S., Eshetu F., Abdella S., Melaku Z., Ajiboye S., Demissie M., Solmo C., Ahmed J., Getaneh Y., Kaydos-Daniels S.C, & Abate E. (2022). Spatial distribution and determinants of HIV prevalence among adults in urban Ethiopia: Findings from the Ethiopia Population-based HIV Impact Assessment Survey (2017–2018). PLoS ONE, 17(7), e0271221.

+ Open protocol

+ Expand

Rapid HIV and HCV Serology Testing

Check if the same lab product or an alternative is used in the 5 most similar protocols

The blood samples were tested for HIV and HCV. HIV serology followed national guidelines including an initial rapid test using SD BIOLINE HIV 1/2 3.0 (Standard Diagnostic Inc., South Korea), coupled with confirmation using two other rapid tests (Alere Determine HIV 1/2 (Abbott Alere Medical Co., Japan, and VIKIA^®HIV1/2, Biomerieux, France). HCV serology was based on a rapid test SD BIOLINE HCV (SD standard Diagnostic Inc, South Korea)).

Reezal A., McNeil B, & Anderson J.G. (1998). Effect of Low-Osmolality Nutrient Media on Growth and Culturability of Campylobacter Species. Applied and Environmental Microbiology, 64(12), 4643-4649.

+ Open protocol

+ Expand

HIV Testing Algorithm in Ethiopia

Check if the same lab product or an alternative is used in the 5 most similar protocols

HIV testing and counselling (HTC) was conducted in the selected HHs using the Ethiopian national HIV testing algorithm for rapid-testing: Wantai (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China) as the first test for screening, then Uni-Gold (HIV 1/2™, Trinity Biotech Plc., Wicklow, Ireland) as confirmatory assay. Finally, Vikia (HIV 1/2, bioMérieux, SA, Marcy-l’Etoile, France) was used as a tiebreaker (Figure 1(B)).

Getaneh Y., Getnet F., Amogne M.D., Liao L., Yi F, & Shao Y. (2023). Burden of hepatitis B virus and syphilis co-infections and its impact on HIV treatment outcome in Ethiopia: nationwide community-based study. Annals of Medicine, 55(2), 2239828.

+ Open protocol

+ Expand

Comprehensive Clinical Microbiology Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols

Aerobic and anaerobic blood culture vials (Becton–Dickinson, Franklin Lakes, NJ, USA) were incubated in the automated BD Bactec 9050 system for a maximum of 5 days or until the culture became positive. Standard culture-based methods were used for species identification [API Test stripes (bioMérieux, Craponne, France) and BBL Enterotubes or BBL Oxi/Ferm Tube (Becton–Dickinson, Franklin Lakes, NJ, USA)]. Coagulase-negative staphylococci and Bacillus spp. were routinely considered contaminants. Streptococcus viridians were regarded contaminants as well, unless the patient had clinical signs of endocarditis or meningitis. As part of a clinical trial requirement, the microbiology laboratory at the ASH successfully participates in regular external quality assurance programs addressing species identification.
For HIV testing, a rapid test was used [Vikia HIV 1/2 (bioMérieux, Craponne, France), or Determine^TM HIV 1/2, (Alere, Yavne, Israel), depending on local availability]. In case of a positive reading, the result was confirmed by VIDAS HIV DUO Ultra (bioMérieux, Craponne, France) and Immunocomb HIV1&2 Bispot (Alere, Yavne, Israel). CD4 counts were done using BD FACS count (Becton–Dickinson, Franklin Lakes, NJ, USA). The Lambaréné method to analyze thick smears was applied to diagnose malaria [11 (link)].

Huson M.A., Kalkman R., Stolp S.M., Janssen S., Alabi A.S., Beyeme J.O., van der Poll T, & Grobusch M.P. (2015). The impact of HIV on presentation and outcome of bacterial sepsis and other causes of acute febrile illness in Gabon. Infection, 43(4), 443-451.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!